Inflammatory Biomarkers Comparison Between Benign Prostatic Hyperplasia Versus Prostate Cancer Patient in Secondary Hospitals, Bogor, Indonesia
Main Article Content
This research aimed to compare inflammatory biomarkers derived from complete blood counts—namely, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)—between BPH and prostate cancer patients. A retrospective study was conducted on 257 patients from two secondary hospitals in Bogor, Indonesia, between January 2021 and June 2025. Subjects were diagnosed with either BPH (n = 212) or prostate cancer (n = 45). Preoperative complete blood counts were used to calculate NLR, PLR, MLR, SII, and SIRI. Group comparisons were performed using the Mann–Whitney U test, and multivariate analysis of variance (MANOVA) was conducted to assess overall biomarker profile differences. Binary logistic regression was applied to evaluate the predictive value of individual biomarkers. PLR was significantly higher in prostate cancer patients (p = 0.007), while other biomarkers did not show significant intergroup differences in univariate analysis. MANOVA revealed a statistically significant difference in overall inflammatory profiles (Pillai’s trace = 0.060, F(5, 251) = 3.208, p = 0.008). Logistic regression identified PLR (p < 0.001), SII (p = 0.035), and SIRI (p = 0.009) as independent predictors of prostate cancer. Inflammatory biomarkers—particularly PLR, SII, and SIRI—may serve as useful markers to differentiate prostate cancer from BPH and offer prognostic insight. These parameters are readily available from routine complete blood counts, making them valuable tools in clinical settings, especially in resource-limited areas. Further prospective studies are recommended to validate their utility and integration into standard diagnostic pathways.
Bailey-Whyte, M., Minas, T. Z., Dorsey, T. H., Smith, C. J., Loffredo, C. A., & Ambs, S. (2023). Systemic inflammation indices and association with prostate cancer survival in a diverse patient cohort. Cancers, 15(6), 1869. https://doi.org/10.3390/cancers15061869
Chen, G., & Feng, L. (2023). Analysis of platelet and monocyte-to-lymphocyte ratio and diabetes mellitus with benign prostatic enlargement. Frontiers in Immunology, 14, 1166265. https://doi.org/10.3389/fimmu.2023.1166265
Chung, M. S., Yang, Y. J., Lee, S. H., & Yoon, B. I. (2020). Association between the neutrophil?to?lymphocyte ratio and intravesical prostatic protrusion in men with benign prostatic hyperplasia. LUTS: Lower Urinary Tract Symptoms, 12(1), 62–67. https://doi.org/10.1111/luts.12275
Devlin, C. M., Simms, M. S., & Maitland, N. J. (2021). Benign prostatic hyperplasia—what do we know? BJU International, 127(4), 389–399. https://doi.org/10.1111/bju.15229
Elmehrath, A. O., Afifi, A. M., Al-Husseini, M. J., Saad, A. M., Wilson, N., Shohdy, K. S., Pilie, P., Sonbol, M. B., & Alhalabi, O. (2021). Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Network Open, 4(8), e2119568.
Fernandes, R., Costa, C., Fernandes, R., & Barros, A. N. (2023). Inflammation in prostate cancer: Exploring the promising role of phenolic compounds as an innovative therapeutic approach. Biomedicines, 11(12), 3140. https://doi.org/10.3390/biomedicines11123140
Horsanali, M. O., Dil, E., Caglayan, A., Ekren, F., & Ozsagir, Y. (2023). The predictive value of the systemic immune-inflammation index for the progression of lower urinary tract symptoms in men. Asian Pacific Journal of Cancer Prevention, 24(11), 3845–3850. https://doi.org/10.31557/APJCP.2023.24.11.3845
Huszno, J., Ko?osza, Z., Mrochem-Kwarciak, J., Telka, E., Jochymek, B., & Miszczyk, L. (2022). Role of neutrophil lymphocyte ratio, platelet lymphocyte ratio, lymphocyte monocyte ratio and platelets in prognosis of patients with prostate cancer. Oncology Letters, 24(3), 1–6. https://doi.org/10.3892/ol.2022.13428
Leslie, S. W., Soon-Sutton, T. L., & Skelton, W. P. (2025). Prostate cancer. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK470550/
Li, F., Hu, H., Gu, S., Chen, X., & Sun, Q. (2015). Platelet to lymphocyte ratio plays an important role in prostate cancer's diagnosis and prognosis. International Journal of Clinical and Experimental Medicine, 8(7), 11746–11751.
Liu, W., Wang, J., Wang, M., Ding, X., Wang, M., & Liu, M. (2024). Association between immune-inflammatory indexes and lower urinary tract symptoms: An analysis of cross-sectional data from the US National Health and Nutrition Examination Survey (2005–2008). BMJ Open, 14(3), e080826. https://doi.org/10.1136/bmjopen-2023-080826
Lorente, D., Mateo, J., Templeton, A. J., Zafeiriou, Z., Bianchini, D., Ferraldeschi, R., et al. (2015). Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Annals of Oncology, 26(4), 750–755. https://doi.org/10.1093/annonc/mdv033
Marchi, F., Pylypiv, N., Parlanti, A., Storti, S., Gaggini, M., Paradossi, U., et al. (2024). Systemic immune-inflammation index and systemic inflammatory response index as predictors of mortality in ST-elevation myocardial infarction. Journal of Clinical Medicine, 13(5), 1256. https://doi.org/10.3390/jcm13051256
Ng, M., Leslie, S. W., & Baradhi, K. M. (2025). Benign prostatic hyperplasia. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK558920/
Safriadi, F., Umbas, R., Danarto, H., Hakim, L., Warli, S. M., Soerohardjo, I., et al. (2022). Panduan penanganan kanker prostat. Ikatan Ahli Urologi Indonesia.
Shi, C., Cao, H., Zeng, G., Yang, L., & Wang, Y. (2024). The relationship between complete blood cell count-derived inflammatory biomarkers and benign prostatic hyperplasia in middle-aged and elderly individuals in the United States: Evidence from NHANES 2001–2008. PLOS ONE, 19(7), e0306860. https://doi.org/10.1371/journal.pone.0306860
Tanagho, E. A., & McAninch, J. W. (2008). Smith's general urology (17th ed.). McGraw-Hill Medical.
Tang, C., Zhang, M., Jia, H., Wang, T., Wu, H., Xu, K., et al. (2024). The systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model. Frontiers in Immunology, 15, 1516737. https://doi.org/10.3389/fimmu.2024.1516737
Tanik, S., Albayrak, S., Zengin, K., Borekci, H., Bakirtas, H., Imamoglu, M. A., et al. (2014). Is the neutrophil-lymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pacific Journal of Cancer Prevention, 15(15), 6375–6379. https://doi.org/10.7314/APJCP.2014.15.15.6375
Tjahjodjati, T., Soebadi, D., Umbas, R., Mochtar, C., Noegroho, B., Danarto, H., et al. (2021). Panduan penatalaksanaan klinis pembesaran prostat jinak (Benign prostatic hyperplasia/BPH) (4th ed.). Ikatan Ahli Urologi Indonesia.
Wang, J., Zhou, X., He, Y., Chen, X., Liu, N., Ding, Z., et al. (2018). Prognostic role of platelet to lymphocyte ratio in prostate cancer: A meta-analysis. Medicine, 97(40), e12504. https://doi.org/10.1097/MD.0000000000012504
Wang, L., Li, X., Liu, M., Zhou, H., & Shao, J. (2024). Association between monocyte-to-lymphocyte ratio and prostate cancer in the U.S. population: A population-based study. Frontiers in Cell and Developmental Biology, 12, 1372731. https://doi.org/10.3389/fcell.2024.1372731
Wu, R., Hu, M., & Zhang, P. (2023). Predictive value of systematic immune-inflammation index combined with Ki-67 index on prognosis of prostate cancer patients after laparoscopic radical prostatectomy. BMC Urology, 23(1), 210. https://doi.org/10.1186/s12894-023-01382-y
Yang, R., Chang, Q., Meng, X., Gao, N., & Wang, W. (2018). Prognostic value of systemic immune-inflammation index in cancer: A meta-analysis. Journal of Cancer, 9(18), 3295–3302. https://doi.org/10.7150/jca.25691
Ye, Y., Zheng, Y., Miao, Q., Ruan, H., & Zhang, X. (2022). Causes of death among prostate cancer patients aged 40 years and older in the United States. Frontiers in Oncology, 12, 914875.
Zhou, Q., Su, S., You, W., Wang, T., Ren, T., & Zhu, L. (2021). Systemic inflammation response index as a prognostic marker in cancer patients: A systematic review and meta-analysis of 38 cohorts. Dose-Response, 19(4), 15593258211064744. https://doi.org/10.1177/15593258211064744
